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Abstract
RA is a chronic, systemic, autoimmune disease characterized by inflammation and degradation of the
joints, causing significant negative impact on quality of life. In addition to joint disease, symptoms and co-
morbidities associated with RA—namely pain, fatigue and mood disorders—are often as debilitating as the
disease itself. The pro-inflammatory cytokine IL-6 plays a critical role in RA-associated pathology.
However, a greater understanding of the translational effects of IL-6 outside of the immune system is
needed. This review discusses our current understanding of emerging aspects of IL-6 in RA-associated
pain, fatigue and mood disorders such as depression and anxiety. This review also describes the clinical
effects of IL-6 inhibition on these symptoms and co-morbidities in patients with RA.
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Rheumatology key messages
. Ubiquitous expression of gp130 and the IL-6 trans-signalling mechanism supports pleiotropic effects of IL-6 in RA.
. IL-6 may have translational effects on RA-associated pain, fatigue and mood disorders.
. Inhibition of IL-6 has demonstrated positive effects on patient-reported pain, fatigue and mood in RA.
Introduction
RA is a common chronic, inflammatory, autoimmune disease
affecting !1% of the world population [1]. For patients with
RA, the ability to perform daily activities and health-related
quality of life are significantly negatively affected [2].
Furthermore, patients with RA of >10 years duration experi-
ence increased mortality compared with the general popu-
lation [3]. Although RA is a disease primarily affecting the
joints, its systemic symptoms and co-morbidities can also
be considered part of the syndrome [4]. Extra-articular mani-
festations of RA affect most organ systems, including the
cardiovascular, nervous, pulmonary and skeletal systems
[1]. Moreover, RA-associated symptoms and co-morbidities
are often intercorrelated. For example, the physical symp-
toms of RA, including pain, inflammation and fatigue, have
important implications on mental health [5]. These chronic
physical symptoms can adversely affect mental health by
altering neural processing [5]. Various studies have demon-
strated significant and positive correlations between pain,
fatigue and mood in patients with RA [6!9]. These symptoms
are recorded as patient-reported outcomes (PROs) and are
vital assessments when measuring RA treatment response
in clinical trials. Despite the growing interest in patient-
centred outcomes in rheumatology, most domains of
health assessed by PROs are not frequently reported in clin-
ical trials [10]. Among 96 randomized controlled trials (RCTs)
conducted in RA and published between 2012 and 2014, the
PROs of pain, fatigue and mood were assessed in only 34,
17 and 5 trials, respectively [11].
It is well established that pro-inflammatory cytokines,
particularly IL-6, are both elevated and involved in RA
pathogenesis [12]. IL-6 is a pleiotropic cytokine with sub-
stantial effects on non-immunological tissues [13]. Beyond
the immune system, IL-6 has been shown to affect
vascular disease, lipid metabolism, insulin resistance,
mitochondrial activities, the neuroendocrine system and
neuropsychological behaviour [14]. It is considered one
of the most important cytokines that mediates the rapid
interplay between the immune system and CNS function
in states of health and disease [13]. The purpose of this
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literature review is to investigate the translational effects
of IL-6 in the presence of RA, specifically in pain, fatigue
and mood disorders. Peer-reviewed primary articles for
this review were obtained from PubMed or from literature
reviews published since 2005. We focused on phase 2
or higher clinical trials reporting pain, fatigue or mood
and pre-clinical mechanistic studies. Search terms
included, but were not limited to RA, IL-6, pain, fatigue,
mood disorders, depression, anxiety, hypothalamic!pitu-
itary!adrenal (HPA) axis, tocilizumab, sarilumab and
sirukumab.
IL-6 Signalling
IL-6 is composed of 184 amino acids and forms a four-
helix protein [15]. Nearly all stromal cells and immune cells
produce IL-6 [14]. The IL-6 receptor (IL-6R) consists of an
a-chain, CD126, and two chains of glycoprotein 130
(gp130) [15!17]. Expression of IL-6R is largely restricted
to hepatocytes, leucocytes and megakaryocytes [14].
Binding of IL-6 to its receptor alone does not result in
signal transduction, as this requires recruitment and
association with the gp130 protein [15]. Universally ex-
pressed, gp130 is a 130 kDa signal-transducing b-recep-
tor subunit, also known as CD130 [14]. When IL-6/IL-6R
are bound, gp130 is recruited and dimerizes and signalling
is initiated (Fig. 1) [18!23].
This process of IL-6 binding to membrane-bound IL-6R
and signalling through the Janus kinase!signal transducer
and activator of transcription (JAK-STAT) pathway is
known as classical signalling [15]. However, many cells,
particularly non-immune cells (i.e. endothelial, smooth
muscle and neural cells), do not express the IL-6R
a-chain but can still respond to IL-6 via binding of soluble
IL-6Ra to membrane-bound gp130, a process called
trans-signalling [15, 24, 25]. The ability to inhibit trans-sig-
nalling using a soluble fusion protein has led to the devel-
opment of a model that suggests IL-6 classical signalling
is responsible for regenerative and protective functions,
whereas IL-6 trans-signalling is involved in the pro-inflam-
matory activity of IL-6 inflammation [19, 25]. For in-depth
reviews of IL-6 signalling, see Rose-John [15] and
Calbrese and Rose-John [20].
As a multifunctional cytokine, IL-6 plays an important
role in many physiological responses, such as acute-
phase response, fever induction, angiogenesis, B and T
cell differentiation and lipid and iron metabolism [26].
Under normal conditions, circulating levels of IL-6
are low; however, in patients with RA, serum and SF
levels of IL-6 and IL-6R are much higher [27!29]. While
IL-6 trans-signalling is involved in the maintenance of
several chronic disease states, it plays a key role in RA
pathogenesis [12]. The combined ubiquitous expression
of gp130 and the trans-signalling pathway enable IL-6
to have pleiotropic effects in RA. Because neuronal
cells express gp130 and can therefore be activated
via IL-6 trans-signalling, IL-6 may have a direct effect
on CNS-related RA symptoms and co-morbidities, such
as pain, fatigue and mood, which are discussed below
[24, 30].
Translational effects of IL-6 in RA
Pain
Pain is the primary reason that patients with inflammatory
arthritis seek care from a rheumatologist and it is the RA-
associated symptom for which most patients desire ef-
fective treatment and meaningful improvement [31, 32].
Despite an ever-growing understanding of pathological
pain mechanisms, pain management still presents a
major challenge in clinical practice. Typical arthritic pain
may be experienced as ongoing pain in the absence of
stimulation, in response to mechanical stimuli (i.e. move-
ments in the working range and joint palpation) or from
normally non-painful warm or cold stimuli, which are all
states of hyperalgesia [29]. Furthermore, while both in-
flammation and joint damage can cause peripheral pain,
some patients with arthritis complain of more severe pain
than the degree of inflammation and joint damage, while
others may complain of joint pain in the absence of in-
flammation and damage, a mechanism known as central
pain [33, 34].
Pain mechanism
Hyperalgesia is the result of sensitization of the nocicep-
tive (pain) system, wherein the excitement threshold
(pain elicitation) for nociceptive neurons is lowered [29].
By targeting the nociceptive system, certain cytokines
have a direct role in the development of hyperalgesia by
acting on neurons themselves [29]. An increasing body of
preclinical evidence suggests that IL-6 plays a dominant
role in pain mechanisms [35]. Neurons and glial cells of the
spinal cord, as well as dorsal root ganglia (DRG), all
express gp130, thereby making these cells susceptible
to IL-6/soluble IL-6R (sIL-6R) trans-signalling [29, 36,
37]. The IL-6 signal transducer gp130 in afferent neurons
is a key regulator of the induction and maintenance of
mechanical hypersensitivity associated with cancer, in-
flammation and nerve injury [38]. Using electrophysiolo-
gical recordings from nociceptors of rat knee joints, IL-6
or IL-6/sIL-6R injections into normal knees caused a long-
lasting sensitization of nociceptive C-fibres for mechanical
stimuli applied to the joint [39]. In a rat model of antigen-
induced arthritis, soluble gp130 (sgp130) injections signifi-
cantly attenuated pain-related behaviour [40]. Knockout
mice lacking gp130 specifically in sensory DRG neurons
(SNS gp130"/") showed reduced inflammation-induced
pain [41]. Application of IL-6/sIL-6R either into rat knee
joints or topically to the spinal cord increased responses
of spinal neurons to mechanical stimulation of the knee
and other parts of the leg, including an expansion of the
receptive field size of the neurons, showing the potential
of IL-6 to induce central sensitization [42]. Furthermore,
development of rat knee inflammation evoked significant
spinal release of IL-6 and spinal application of sgp130
attenuated the generation of spinal hyperexcitability
during the development of inflammation [42]. Collectively
these preclinical studies demonstrate that IL-6 is a key
mediator of pain through direct action on the nociceptive
system.
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Anti-IL-6 agents and pain
The positive effects of IL-6 inhibition on patient-reported
pain have been demonstrated (as secondary or explora-
tory endpoints) in phase 3 trials of the IL-6R antagonists
tocilizumab, sarilumab and sirukumab in patients with
moderate to severe RA (Table 1). Tocilizumab, sarilumab
and sirukumab are mAbs that target both soluble and
membrane-bound receptors for IL-6, thereby preventing
both classical and trans-signalling [43!45]. Although
there is no gold standard for pain measurement, in
rheumatology populations, pain is often measured on a
visual analogue scale (VAS), a single-item unidimensional
measurement of pain intensity that has been shown to be
reliable, simple and applicable to a variety of populations
and settings [46]. The VAS scale (in millimetres) is generally
anchored by no pain (0) to worst imaginable pain (100) and
patients report current pain or pain within the last 24h [46].
In the Tocilizumab Pivotal Trial in Methotrexate
Inadequate Responders (OPTION) and Tocilizumab
Safety and the Prevention of Structural Joint Damage
(LITHE) studies, patients with RA experienced significant
improvement in pain, as measured by improvement in
mean VAS scores, with tocilizumab 4 and 8mg/kg every
4weeks (q4w) plus MTX at both 24 and 52 weeks [47, 48].
Improvements in mean VAS scores were also modestly
maintained through 104 weeks with tocilizumab [49]. The
Tocilizumab and DMARDs: Achievements in Rheumatoid
Arthritis (TAMARA) study, a real-world study of patients with
RA treated with tocilizumab plus a DMARD, reported modest
improvements from baseline in pain within the first 4 weeks of
treatment, which were sustained through week 24 [50].
However, when tocilizumab monotherapy was compared
with MTX monotherapy in the Actemra Versus Methotrexate
Double-blind Investigative Trial in Monotherapy (AMBITION)
study, only a slight improvement in pain was reported at
week 24 [51].
In the Evaluation of Sarilumab (SAR153191/REGN88) on
Top of Methotrexate in Rheumatoid Arthritis Patients
(MOBILITY) study, patients with RA treated with sarilumab
150 or 200mg every 2 weeks (q2w) plus MTX reported a
significant improvement in pain compared with placebo plus
MTX at 2 weeks of treatment that was sustained through
weeks 24 and 52 [52]. Similarly, in the To Evaluate the Effect
of SAR153191 (REGN88) Added to Other RA Drugs in
Patients With RA Who Are Not Responding to or Intolerant
of Anti-TNF Therapy (TARGET) study, patients with RA
treated with sarilumab 150 or 200mg q2w plus conventional
synthetic DMARDs (csDMARDs) also reported a significant
improvement in pain vs placebo at both 12 and 24 weeks
[53]. Sarilumab monotherapy also led to a significant
improvement in the VAS score compared with adalimumab
monotherapy at 24 weeks [54].
FIG. 1 Signalling of IL-6 via the classical and trans-signalling pathways
In classical signalling, IL-6 binds membrane-bound receptors on a few peripheral cells, including hepatocytes and
leucocytes. The IL-6/IL-6R complex does not result in signalling, as association with the ubiquitously expressed trans-
ducing protein gp130 is required to initiate signalling. In trans-signalling, membrane-bound IL-6R is made soluble by
cleavage with metalloproteases. Soluble IL-6R binds IL-6 to form the IL-6/IL-6R complex, which then binds membrane-
bound gp130. This form of trans-signalling does not require membrane-bound IL-6R and can therefore occur in any cell
type that expresses membrane-bound gp130, including cells of the CNS, neurons, astrocytes and microglia. gp130:
glycoprotein 130; JAK: Janus kinase; STAT: signal transducer and activator of transcription; mIL-6Ra: membrane-bound
IL-6 receptor alpha; sIL-6Ra: soluble IL-6 receptor alpha.
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Sirukumab, a mAb that binds IL-6, demonstrated a
dose!response improvement in pain in the A Study of
CNTO 136 (Sirukumab), a Human Anti-IL-6 Monoclonal
Antibody, Administered Subcutaneously, in Patients With
Active Rheumatoid Arthritis Despite Anti-TNF-Alpha
Therapy (SIRROUND-T) study in patients with active RA,
with the lowest dose (50mg q4w) providing a 26.7%
improvement in the VAS score and the highest dose
(100mg q2w) providing a 30.5% improvement at week 24
compared with a 1.5% improvement with placebo [55]. This
was maintained at 52 weeks for both sirukumab 50 and
100mg (28.8 and 38.7% improvement, respectively) [55].
Fatigue
Like pain, fatigue is a debilitating symptom that is nearly
universally experienced by patients with RA (>80%), often
daily, and is typically rated as impactful and as important
as pain [7, 56]. According to the US Food and Drug
Administration, persistent severe fatigue occurs in 40%
of patients with RA [57]. Qualitative interview data
from patients with RA found that fatigue is a common,
often severe experience, with consequences affecting
every aspect of daily life [56]. They reported trying differ-
ent self-management strategies with variable success,
and most did not discuss their symptoms with their
doctors or felt that the topic was dismissed if they did
[56]. In a recent systematic review of RA-associated
fatigue, 42 relevant studies were identified, generating
25 possible predictors of fatigue [58]. The three variables
with the highest probability of being involved with
RA-associated fatigue were mood disorders (depres-
sion/depressive mood), pain and disability/diminished
physical functioning [58].
Fatigue and the HPA axis
Whereas the causality of RA-associated fatigue is likely
multidimensional, involving inflammation, pain, anaemia,
poor sleep and psychosocial factors, there is a growing
body of evidence implicating the involvement of IL-6 and
the HPA axis (Fig. 2) [27, 56, 59]. The HPA axis is a primary
component of the stress system that is involved in the
maintenance or reinstatement of homeostasis in response
to physical (e.g. injury or infection) or physiological (e.g.
anticipation of pain) stressors [60, 61]. Dysfunction of the
HPA axis, specifically mediated by low circulating levels of
cortisol, has been associated with chronic fatigue [62].
Briefly, perceived stress initiates a signal within the para-
ventricular nucleus of the hypothalamus. Neurons then
secrete corticotropin-releasing hormone (CRH), which
binds to specific receptors in the anterior pituitary [63].
This then stimulates the synthesis and release of adreno-
corticotropic hormone from the anterior pituitary into the
TABLE 1 PROs of pain in studies of anti-IL-6R agents in moderate to severe RAa
Drug Study Treatment n
Pain (VAS)
Baseline Treatment visit
Tocilizumab Week 24
OPTION [47] 4 mg/kg q4w + MTX qw 213 60.7 (21.0) "25.0** NR
8 mg/kg q4w + MTX qw 205 59.9 (22.4) "29.8*
Placebo q4w + MTX qw 204 57.3 (22.2) "14.0
Week 24
AMBITION [51] 8 mg/kg q4w 268 58.7 (22.9) "31.9 NR
MTX qw 262 61.5 (20.6) "29.9
Week 4 Week 24
TAMARA [50] 8 mg/kg q4w + DMARD 286b 60.4 (21.5) 36.0 (26.7) 23.6 (26.3)
Week 52 Week 104c
LITHE [48, 49] 4 mg/kg q4w + MTX qw 399 NR "23.1*** "26.6 (25.4)
8 mg/kg q4w + MTX qw 398 "26.2* "28.9 (25.5)
Placebo q4w + MTX qw 393 "15.1 "25.6 (24.4)
Sarilumab Week 24 Week 52
MOBILITY [52] 150 mg q2w + MTX qw 400 65.4 (21.4) "28.5 (1.4)* "32.7 (1.4)*
200 mg q2w + MTX qw 399 66.7 (21.4) "31.8 (1.3)* "33.1 (1.4)*
Placebo q2w + MTX qw 398 63.7 (19.9) "15.4 (1.4) "19.3 (1.6)
Week 12 Week 24
TARGET [53] 150 mg q2w + csDMARDs 181 71.0 (19.3) "26.9 (1.9)* "31.9 (2.1)**
200 mg q2w + csDMARDs 184 74.9 (18.4) "30.6 (1.9)* "33.7 (2.0)*
Placebo q2w + csDMARDs 181 71.6 (18.2) "15.1 (1.9) "21.3 (2.3)
Week 24
MONARCH [54] 200 mg q2w 184 70.9 (18.8) "36.2 (1.8)** NR
Adalimumab 40 mg q2w 185 70.3 (19.3) "27.4 (1.8)
Values given as mean (S.D.). aOnly phase 3 clinical trials reporting patient-reported pain were included in this table. bData
presented are for patients with inadequate response to conventional DMARDs; n for this specific population is not given in the
source. cAt week 104, n=228, 248 and 137 for tocilizumab 4mg/kg, tocilizumab 8mg/kg and placebo, respectively.
*P4 0.0001, **P< 0.001, ***P<0.05. NR: not reported; qw: every week; q2w: every 2 weeks; q4w: every 4 weeks.
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circulatory system [63]. This complex HPA axis relies on
bidirectional communication between the neuroendocrine
and immune systems [60]. Inflammatory cytokines, par-
ticularly TNF-a, IL-1b and IL-6, can stimulate the HPA
axis alone or synergistically [64]. Among these, IL-6
plays one of the more dominant roles in immune stimula-
tion of the HPA axis, particularly during chronic inflamma-
tory stress such as in RA [64]. In fact, administration of
IL-6 into humans stimulates the HPA axis even more
potently than high doses of CRH [65].
Growing evidence suggests that the HPA axis stress
response, via its dysfunction, plays an important role in
RA, particularly in its interaction with the immune system
[66]. Untreated patients with RA have hypersecretion of
adrenocorticotropic hormone without the reciprocal in-
crease in cortisol [66]. The HPA axis and IL-6 plasma
levels were assessed in a study of 50 patients with RA
of variable duration, ranging from recent onset (<1 year)
to long-standing (>5 years) active disease [27]. Compared
with healthy controls, patients with RA had impaired ac-
tivity of the HPA axis, with significantly decreased cortisol
levels and elevated IL-6 [27]. It is hypothesized that
altered adrenal activity in RA may be responsible for
decreased cortisol; however, the failure of elevated
levels of IL-6 to stimulate cortisol suggests a possible
hypothalamic defect as well [27]. The complexity of this
system and these observations underscore the ability of
hormones and cytokines to influence each other.
IL-6 is also involved in normal sleep regulation [13, 67].
Healthy individuals deprived of sleep had daytime over-
secretion of IL-6, and s.c. administration of IL-6 into
healthy individuals significantly altered sleep structure
and promoted symptoms of fatigue [67, 68]. Clinical stu-
dies suggest a model wherein IL-6 secretion and HPA axis
activation together result in fatigue and poor sleep [69].
For example, IL-6-induced HPA axis activation in patients
with RA resulted in transient hypercortisolemia during the
early hours of sleep, which may explain the poor sleep
quality during this period [70]. In addition to its effect on
the HPA axis, IL-6 may also exacerbate RA-associated
fatigue through its involvement in disease-associated an-
aemia [13]. This may be because IL-6 drives hepcidin,
which blocks ferroportin-mediated transfer of cellular
iron [13].
Anti-IL-6 agents and fatigue
Assessing fatigue in RA clinical trials was initially recom-
mended in 2007 by the OMERACT group, but as of 2015,
this measure has only been specifically reported in !18%
of RCTs [11]. The Functional Assessment of Chronic
Illness Therapy!Fatigue (FACIT-F) scale is a 13-item
PRO questionnaire commonly used in RCTs of RA that
has demonstrated reliability, validity and sensitivity for
rating the severity of fatigue symptoms [11, 71]. In RA,
the FACIT-F is scored on a scale of 0!52, with higher
scores reflecting less fatigue and a minimally important
difference requiring a 3!4 point change [71]. In the
recent Cochrane Review of biologic interventions for fa-
tigue in RA, 32 studies (20 anti-TNF and 12 non-anti-TNF
biologic agents, including the anti-IL-6 agent tocilizumab)
were included in the meta-analysis [72]. Overall, the study
found a statistically significant reduction in fatigue in pa-
tients with RA when treated with biologics [standardized
mean difference (SMD) "0.43 (95% CI "0.49, "0.38);
P< 0.00001]. Anti-TNF agents had an SMD of "0.42
and non-anti-TNF agents had an SMD of "0.46 [72].
After a median of 24 weeks of treatment, the SMD
in FACIT-F scores between anti-TNF and non-anti-TNF
biologic agents and control groups was 6.3 and 6.9 U,
respectively [72]. The authors were unable to pool data
on pain or mood for the meta-analysis because of a lack
of assessment or reported data [72].
The positive effects of IL-6 inhibition on symptoms of fa-
tigue by tocilizumab, sarilumab and sirukumab in patients
with moderate to severe RA, as assessed by FACIT-F, have
been demonstrated in phase 3 clinical studies (Table 2). In
the OPTION study, patients experienced a significant reduc-
tion of fatigue with tocilizumab 4 and 8mg/kg q4w plus MTX
compared with placebo plus MTX at 24 weeks [47]. In the
TAMARA study, tocilizumab reduced fatigue within 4 weeks
and improvement continued over 24 weeks [50]. Fragiadaki
et al. [73] reported significant improvement of self-reported
sleepiness, sleep quality and fatigue in 15 patients with
active RA receiving tocilizumab 8mg/kg q4w (mean
FACIT-F improvement over baseline at 6 months = 17.7;
P< 0.00001). In a phase 4 study of 325 patients with RA,
FIG. 2 The HPA axis in RA
Pro-inflammatory cytokines such as IL-6, TNF-a and IL-1b
stimulate cortisol and CRH release by acting at all three
levels of the HPA axis (solid green lines). As a result,
glucocorticoids regulate their own production through
negative feedback on the upper levels of the HPA axis,
including CRH in the PVN of the hypothalamus and ACTH
in the anterior pituitary (dashed red lines). ACTH: adre-
nocorticotropic hormone; CRH: corticotropin-releasing
hormone; PVN: paraventricular nucleus.
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tocilizumab monotherapy was associated with a modest
improvement in fatigue from baseline compared with adali-
mumab monotherapy at 24 weeks [74].
In the MOBILITY study, patients receiving sarilumab
demonstrated a significant improvement in FACIT-F scores
as early as 2 weeks that were sustained through 52 weeks
compared with placebo [52]. Similarly, in the TARGET study,
patients receiving sarilumab plus csDMARDs reported a
significant improvement in FACIT-F scores vs placebo at
both 12 and 24 weeks [53]. Sarilumab monotherapy also
led to a modest improvement in FACIT-F scores compared
with adalimumab monotherapy at 24 weeks [54]. Alleviation
of fatigue appears to be one of the first beneficial effects
that patients with RA may experience when using biologic
therapies that block IL-6 signalling [13].
In the SIRROUND-T study, patients receiving sirukumab
50mg q4w or 100mg q2w demonstrated a significant
improvement in FACIT-F scores at 24 weeks compared with
placebo[55]. Improvementwasalsoobservedat52weeks[55].
Mood disorders
More than one-third of patients with RA suffer from mood
disorders, particularly depression and anxiety [5, 75, 76].
Depression (defined as past or current symptoms) was the
most commonly observed co-morbidity among 3920 patients
with RA as assessed by rheumatologists during face-to-face
interviews and medical records review in the Comorbidities in
Rheumatoid Arthritis (COMORA) cross-sectional study [4]. A
recent systematic review and meta-analysis of 72 studies in
>13000 patients with RA found the prevalence of depression
to be !38% [76]. Despite its prevalence and effect on
quality of life, mental health co-morbidity is rarely measured
in rheumatology research or in clinical practice, with min-
imal published research reporting mental health as an
outcome [77].
Mood disorder mechanism
Although there may be several proposed mechanisms
underlying the relationship between RA and mood disorders,
a strong link to IL-6 has been made. Animal models lacking
IL-6 or those treated with IL-6-blocking antibody were found
to be resilient to social stress, suggesting a potentially im-
portant role for the cytokine in the development of depres-
sion or anxiety [78]. In healthy individuals undergoing
psychosocial distress, low peripheral IL-6 levels can predict
earlier resolution of negative mood [79]. Conversely, admin-
istration of IL-6 into healthy individuals significantly de-
pressed self-reported mood [68]. Both clinical studies and
recent meta-analyses have indicated that IL-6 is the most
consistently elevated cytokine in the blood of patients with
major depressive disorder [80!82]. Although there is limited
understanding of the mechanism(s) by which IL-6 signalling
may contribute to manifestations of depression, a few
hypotheses exist [83]. One hypothesis is that genetic poly-
morphisms may contribute to psychopathological symptoms
since a functional single-nucleotide polymorphism in the
promoter region of the IL-6 gene has been shown to be
associated with decreased IL-6 expression and plasma
TABLE 2 PROs of fatigue in studies of anti-IL-6R agents in moderate to severe RAa
Drug Study Treatment n
Fatigue (FACIT-F)
Baseline Treatment visit
Tocilizumab Week 24
OPTION [47] 4 mg/kg q4w + MTX qw 213 27.0 (11.5) 7.3** NR
8 mg/kg q4w + MTX qw 205 27.7 (10.6) 8.6*
Placebo q4w + MTX qw 204 26.7 (11.1) 4.0
Week 24
ADACTA [74] 8 mg/kg q4w 163 NR 11.4 NR
Adalimumab 40 mg q2w 162 8.9
Sarilumab Week 24 Week 52
MOBILITY [52] 150 mg q2w + MTX qw 400 26.3 (9.8) 8.6 (0.5)* 9.1 (0.5)*
200 mg q2w + MTX qw 399 25.9 (10.4) 9.2 (0.5)* 9.2 (0.5)*
Placebo q2w + MTX qw 398 27.2 (10.4) 5.8 (0.5) 6.1 (0.5)
Week 12 Week 24
TARGET [53] 150 mg q2w + csDMARDs 181 23.5 (10.6) 8.0 (0.7)*** 9.9 (0.8)***
200 mg q2w + csDMARDs 184 23.1 (10.8) 9.5 (0.7)* 10.1 (0.8)***
Placebo q2w + csDMARDs 181 23.7 (10.8) 5.6 (0.7) 6.8 (0.9)
Week 24
MONARCH [54] 200 mg q2w 184 23.6 (8.9) 10.2 (0.7) NR
Adalimumab 40 mg q2w 185 24.4 (10.3) 8.4 (0.7)
Sirukumab Week 24 Week 52
SIRROUND-T [55] 50 mg q4w 292 NR 6.6 (10.8)* 7.5 (10.1)
100 mg q2w 292 NR 5.6 (9.1)* 7.0 (10.4)
Placebo q2w 294 NR 1.9 (8.8)
Values given as mean (S.D.). aOnly phase 3 clinical trials reporting patient-reported fatigue were included in this table.
*P4 0.0001, **P< 0.01, ***P< 0.05. NR: not reported; qw: every week; q2w: every 2 weeks; q4w: every 4 weeks.
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concentrations [84]. A prospective study in patients receiving
pegylated IFN-a for treatment of hepatitis C, designed on the
basis of previous studies that showed a correlation between
increased plasma IL-6 during IFN-a treatment and psycho-
pathological symptom severity, found that a low IL-6 synthe-
sizing genotype was significantly associated with fewer
symptoms of depression (P=0.002) [84, 85]. Cytokines
may also cause depression through hyperactivation of the
HPA axis. Dysregulation of the HPA axis has been asso-
ciated with psychopathologies such as depression, panic
disorder and anxiety [63, 86]. Chronic stress has been
shown to activate IL-6 and signal through the JAK-STAT3
pathway in the hypothalamus of rats as well as induce a
sustained corticosterone response [86].
Anti-IL-6 agents and mood
A common measure of mental health symptoms such as
depression used in clinical trials of RA is the mental com-
ponent summary (MCS) of the 36-item Short Form Health
Survey (SF-36). The MCS is calculated by positively
weighting the psychological subscales (vitality, social
function, role emotional and mental health) and negatively
weighting the physical subscales (physical function, role
physical, bodily pain and global health) of the SF-36 [87].
The minimally important change in the SF-36 MCS for RA
is 3.1 [11]. A study investigating the accuracy of SF-36
MCS scores in identifying the presence of mood disorders
(major depressive disorder or anxiety) in patients with RA
found that optimal use of the subscale required a thresh-
old of 438 [87]. Positive effects of IL-6 inhibition on
patient-reported mental health, as assessed by the SF-
36 MCS score, have been demonstrated in several
phase 3 studies of tocilizumab, sarilumab and sirukumab
in patients with moderate to severe RA (Table 3).
Patients experienced significant improvement in mean
SF-36 MCS scores with tocilizumab 4 and 8mg/kg q4w
plus MTX compared with placebo plus MTX at 24 weeks
in the OPTION study [47]. In a 24 week phase 4 study,
tocilizumab monotherapy was associated with significant
improvement in SF-36 MCS scores compared with adali-
mumab monotherapy [74].
In the MOBILITY study, patients treated with sarilumab 150
and 200mg q2w plus MTX reported a significant improve-
ment in SF-36 MCS scores at 24 and 52 weeks [52]. In the
TARGET study, patients treated with sarilumab plus
csDMARDs also reported improvement in SF-36 MCS
scores at both 12 and 24 weeks vs placebo [53]. Treatment
with sarilumab monotherapy showed a trend toward greater
improvement in SF-36 MCS scores vs adalimumab mono-
therapy at 24 weeks [54].
In the SIRROUND-T study, patients receiving sirukumab
50mg q4w or 100mg q2w demonstrated significant im-
provements in SF-36 MCS scores at 24 weeks vs placebo
[55]. Improvement was also observed at 52 weeks [55].
Discussion
Whereas RA primarily involves the joints, co-morbidities
and systemic extra-articular symptoms such as pain,
fatigue and mood disorders are often just as debilitating
TABLE 3 PROs of mood in studies of anti-IL-6R agents in moderate to severe RAa
Drug Study Treatment n
Mood (SF-36 MCS)
Baseline Treatment visit
Tocilizumab Week 24
OPTION [47] 4 mg/kg q4w + MTX qw 213 40.1 (11.8) 5.7**** NR
8 mg/kg q4w + MTX qw 205 40.9 (10.6) 7.3***
Placebo q4w + MTX qw 204 39.1 (11.0) 2.7
Week 24
ADACTA [74] 8 mg/kg q4w 163 NR 7.9**** NR
Adalimumab 40 mg q2w 162 5.0
Sarilumab Week 24 Week 52
MOBILITY [52] 150 mg q2w + MTX qw 400 39.0 (11.3) 5.7 (0.6)**** 7.1 (0.6)
200 mg q2w + MTX qw 399 38.7 (12.0) 8.2 (0.6)* 8.4 (0.6)**
Placebo q2w + MTX qw 398 38.9 (11.4) 3.9 (0.6) 5.5 (0.7)
Week 12 Week 24
TARGET [53] 150 mg q2w + csDMARDs 181 38.6 (11.4) 5.1 (0.8) 6.3 (0.8)
200 mg q2w + csDMARDs 184 39.1 (11.4) 6.5 (0.7)**** 6.8 (0.8)
Placebo q2w + csDMARDs 181 38.5 (12.6) 3.5 (0.7) 4.7 (0.9)
Week 24
MONARCH [54] 200 mg q2w 184 36.4 (10.4) 7.9 (0.8) NR
Adalimumab 40 mg q2w 185 36.9 (11.6) 6.8 (0.8)
Sirukumab Week 24 Week 52
SIRROUND-T [55] 50 mg q4w 292 NR 3.9 (10.7)** 4.7 (10.1)
100 mg q2w 292 NR 4.1 (9.3)** 4.9 (10.5)
Placebo q2w 294 NR 1.1 (8.9)
Values given as mean (S.D.). aOnly phase 3 clinical trials reporting patient-reported mood were included in this table.
*P4 0.0001, **P< 0.001, ***P< 0.01, ****P< 0.05. NR: not reported; qw: every week; q2w: every 2 weeks; q4w: every 4 weeks.
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and important to patients—so much so that their utility as
clinical trial endpoints, in the form of PROs, is increasingly
becoming a priority among rheumatology organizations
and advocacy groups. The substantial overlap and posi-
tive correlation between pain, fatigue and mood suggest
the possibility of a common underlying mechanism (Fig. 3)
[88]. IL-6 has long been viewed as playing a dominant role
in the pathogenesis of RA because of its pro-inflammatory
effects; however, the far-reaching translational effects of
IL-6 in RA are beginning to be appreciated. These effects
are supported by the ubiquitous expression of gp130 and
the IL-6 trans-signalling mechanism. Expression of gp130
throughout the nervous system, particularly on neurons,
glial cells and DRG, enables IL-6 to mediate pain by dir-
ectly acting on the nociceptive system. In addition to data
supporting the role of IL-6 in RA-associated pain, conver-
ging lines of evidence also support the role of IL-6 in other
pathological pain conditions, including bone cancer,
chemotherapy-induced peripheral neuropathy, peripheral
nerve injury and spinal cord injury [35].
Data generated from both animal and human studies
support the hypothesis that the HPA axis plays a critical
role in RA [89]. Deficiencies in the HPA axis, particularly in
glucocorticoid and cortisol levels, may result in a wide
range of clinical effects, including the exacerbation of
acute to chronic RA [27]. Fatigue and mood alterations,
presenting as depression, anxiety or both, are also influ-
enced by the HPA axis. A dysfunctional HPA axis that
results in alterations of cortisol production is the basis of
many sleep conditions. IL-6 has been described as a
putative sleep factor because of its circadian secretion
correlation [69]. In addition to RA-associated fatigue,
systemic IL-6 levels are also upregulated in several
sleep disorders, such as chronic fatigue syndrome, nar-
colepsy and obstructive sleep apnoea [62, 69]. Altered
HPA axis activity is observed in several neurodegenerative
conditions that have a high incidence of co-morbid
depression, such as Alzheimer’s disease, Parkinson’s
disease and Huntington’s disease [63].
The hypothesis that IL-6 contributes to RA-associated
symptoms and co-morbidities through its effects on the
HPA axis is currently only supported by preclinical data.
Functional and clinical data are needed to support a
mechanism of action for IL-6 as a modulator of HPA
axis activity. Furthermore, there is an ever-growing body
of evidence supporting a link between psychosocial func-
tioning, disease activity and associated pain in RA [66].
Teasing apart the underlying mechanisms remains a chal-
lenge as the interrelationships between psychosocial,
neuroendocrine and immune variables, and their potential
effects on RA exacerbation, are complex (Fig. 3).
Inhibitors of IL-6 reduced pain and fatigue and improved
mood. Currently it is unclear whether this is due to suppres-
sion of inflammation and RA or a direct effect of inhibiting
IL-6. Further translational research is needed to understand
whether IL-6 inhibition confers additional advantages in
alleviating these symptoms, particularly whether patients
with hyperalgesia, severe fatigue or concomitant depression
will derive greater benefits from IL-6 inhibition.
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